CD33-CLL1 multiplex-engineered eHSC therapy (Vor Biopharma)

N/A

Report date: 2024/06/12 10:42:28

Base Information

Drug NameCD33-CLL1 multiplex-engineered eHSC therapy (Vor Biopharma)

Drug Alias NameCD33-CLL1 Treatment System (Vor Biopharma)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulators

TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVor Biopharma Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

ATC CodeN/A